Please login to the form below

Not currently logged in
Email:
Password:

Fishawack MBO

Fishawack communications announced on March 14 that members of its management team bought out the company and became equity partners.

Fishawack communications announced on March 14 that members of its management team bought out the company and became equity partners.

The management buy out (MBO) by four senior members of it was funded by venture capitalists YFM Private Equity.

The founding partners of Fishawack communications, a company that caters for the healthcare and pharmaceutical industry, will remain significant shareholders.

Tim Mustill, managing director and founding partner of Fishawack, said: "We are proud to have grown into one the largest independent communications agencies in the UK, and have entered 2008 with renewed vigour and focus."

Fishawack client portfolio includes pharma companies such as GlaxoSmithKline, Roche, and Bayer.

Oliver Dennis, founding partner of Fishawack, said: "Fishawack is a strong brand with a solid and growing reputation for excellence. We are now well placed to deliver on our ambitious growth and development plans."

17th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics